Stay current on the latest news from Wisconsin’s innovation community, starting with these recent headlines:

—Mallinckrodt finalized its acquisition of Madison-based Stratatech, which is developing cell-based human skin tissue for treating burn wounds, the Wisconsin State Journal reported. Mallinckrodt (NYSE: MNK), a drugmaker based in the U.K. whose clients include burn centers, was reportedly one of several companies vying to purchase Stratatech. Its operations and 55 employees are expected to remain in Madison, as a Mallinckrodt spokesperson told Xconomy last month.

Read the full story here.